John Bedard
Member of the Scientific Advisory Board

John recently retired from Bristol-Myers Squibb where he was Vice President, FDA Liaison and Global Strategy. He spent the last 15 years of his career at BMS directing development and registration programs for phases I-IV. He also directed the worldwide GLP and GCP programs. Earlier in his career John was Group Director, U.S. Regulatory Affairs at Smith Kline and French Laboratories and Assistant Director, the U.S. Regulatory Affairs at Wyeth-Ayerst.

Over his 25-year career, John has directed development and registration programs in hypertension, heart failure, post-MI therapy, hyperlipidemia, type II diabetes, ulcer disease, psoriasis, migraine, and female hirsutism. A partial list of development programs included in John’s experience are: Pravachol for hyperlipidemia, primary and secondary prevention of MI, stroke and revascularization; Capoten for post MI and diabetic nephropathy; Monopril for hypertension; Avapro for hypertension; Glucovance for type II diabetes; Glucophage XR for type II diabetes; Dovonex for psoriasis; Vaniqa for female hirsutism; Tagamet for stress related bleeding; Tagamet QD for gastric ulcer; Inderal for post MI; and Inderal LA for hypertension, angina and migraine.

John has contributed to DIA, PERI and other associations devoted to education in drug development and registration. He was Lecturer, DIA Course on INDs and NDAs, Lecturer – PERI Course: How to Prepare for FDA Advisory Committee Meetings. Furthermore, he was Chairman, Delaware Valley Regulatory Affairs, as well as Chairman, DIA Special Interest Advisory Committee for Regulatory Affairs.

John is a member of DIA, NY Academy of Sciences, and American Association for the Advancement of Science (AAAS). He received a BA in Chemistry from Rutgers University and an M.S. in Chemistry from St. Josephs’ University.

info@pharmregservices.com